NRGN

Inoviv Launches NeuroKey-3™, A Quantitative Multiplexed IP-MS Assay to Measure Key Low-Level Markers in Neurodegeneration

Retrieved on: 
Friday, March 1, 2024
BDNF, Lipid, FDA, Neuroinflammation, Alzheimer's disease, NRGN, Disease, Biomarker, Protein, Clinical trial, Plasma, Dementia

NeuroKey-3™ is a proprietary method providing absolute quantification of multiple proteins in a single IP-MS assay.

Key Points: 
  • NeuroKey-3™ is a proprietary method providing absolute quantification of multiple proteins in a single IP-MS assay.
  • NeuroKey-3™ is now commercially available through Inoviv for drug developers to gather valuable data for their clinical trials.
  • LONDON, March 1, 2024 /PRNewswire/ -- Biomarker pioneer, Inoviv, announces the launch of its proprietary NeuroKey-3™ assay, an end-to-end service offering to measure key low-level markers in neurodegeneration in human plasma.
  • "NeuroKey-3 provides highly accurate and fully quantitative insights into proteins linked to neurodegeneration and can be adapted to provide definitive data into post-translational modifications, other proteins, lipids, and metabolites."

NRGene Establishes Supree, a Food-Tech Company developing Self-Drying Fruits and Vegetables

Retrieved on: 
Tuesday, January 30, 2024
Taste, NESS, Vitamin, Farmer, Meat, Heat, Partnership, Salad, Freezing, NRGN, USD, Snack, Restaurant, Claro, Antioxidant, Food preservation

NESS ZIONA, Israel, Jan. 30, 2024 /PRNewswire/ -- NRGene Technologies Ltd. (TASE: NRGN) is pleased to introduce Supree (Supree-Zanim), its newly established FoodTech subsidiary, specializes in innovative fruit and vegetable varieties that naturally self-dry on the vine while maintaining nutritional value and flavor.

Key Points: 
  • The uniqueness of these varieties is in their skin's structure that is filled with microcracks which enables natural moisture evaporation.
  • Supree's semi-dried tomatoes are perfect for various culinary applications from snacks, salads and cooked dishes, baked goods, and even desserts.
  • The thawed product retains its quality, texture, and nutritional value and is available throughout the year, regardless of growing season.
  • Tomato powder derived from these tomatoes enriches processed food products across various industries, including meat products, meat substitutes, healthy beverages, and snacks.

NRGene Establishes Supree, a Food-Tech Company developing Self-Drying Fruits and Vegetables

Retrieved on: 
Tuesday, January 30, 2024
Taste, NESS, Vitamin, Farmer, Meat, Heat, Partnership, Salad, Freezing, NRGN, USD, Snack, Restaurant, Claro, Antioxidant, Food preservation

NESS ZIONA, Israel, Jan. 30, 2024 /PRNewswire/ -- NRGene Technologies Ltd. (TASE: NRGN) is pleased to introduce Supree (Supree-Zanim), its newly established FoodTech subsidiary, specializes in innovative fruit and vegetable varieties that naturally self-dry on the vine while maintaining nutritional value and flavor.

Key Points: 
  • The uniqueness of these varieties is in their skin's structure that is filled with microcracks which enables natural moisture evaporation.
  • Supree's semi-dried tomatoes are perfect for various culinary applications from snacks, salads and cooked dishes, baked goods, and even desserts.
  • The thawed product retains its quality, texture, and nutritional value and is available throughout the year, regardless of growing season.
  • Tomato powder derived from these tomatoes enriches processed food products across various industries, including meat products, meat substitutes, healthy beverages, and snacks.

Above Food Corp. to Acquire AI-based Genomic Assets, Intellectual Property and Trait Development Technology Licensing Rights from NRGene

Retrieved on: 
Tuesday, September 26, 2023
Intellectual property, DNA, Partnership, Biting, Food industry, Genomics, Farmer, APA, Business, Seedling, Livestock, Research, NRGN, Animal, TASE, AI, Food security, CO2, Food, Agriculture, Rapeseed oil

NRGene will receive a combination of cash and stock-based consideration, as well as royalties from commercialization of specific projects.

Key Points: 
  • NRGene will receive a combination of cash and stock-based consideration, as well as royalties from commercialization of specific projects.
  • NRGene's unique AI genomic technology has already demonstrated its effectiveness in over 300 projects spanning various key crops.
  • This technology is intended to facilitate efficient trait mapping and introgression of desirable traits into elite crops.
  • By joining forces, we believe we can pave the way towards a worldwide impact on global agricultural productivity and food security".

Bühler and NRGene collaborate to increase competitiveness of black soldier fly industry

Retrieved on: 
Wednesday, September 6, 2023
Food, Partnership, BSF, Genetics, Agriculture, Livestock, Genomics, NRGN, Traction, Animal, NESS, Engineering, TASE, Water, Pet, Health, Meat

The two companies are combining their expertise to provide solutions and services to this rapidly evolving industry.

Key Points: 
  • The two companies are combining their expertise to provide solutions and services to this rapidly evolving industry.
  • The partnership between Bühler and NRGene offers BSF producers a comprehensive solution that incorporates Bühler's high-end equipment and engineering capabilities and NRGene's novel genetics and AI-based genomics tools.
  • We are excited to partner with Bühler as we move towards a cost-efficient industry scaleup," says Dr. Gil Ronen, NRGene's CEO and Founder.
  • Black soldier fly is considered one of the most sustainable meat alternatives for carnivorous pets and farm animals.

Bühler and NRGene collaborate to increase competitiveness of black soldier fly industry

Retrieved on: 
Wednesday, September 6, 2023
Food, Partnership, BSF, Genetics, Agriculture, Livestock, Genomics, NRGN, Traction, Animal, NESS, Engineering, TASE, Water, Pet, Health, Meat

The two companies are combining their expertise to provide solutions and services to this rapidly evolving industry.

Key Points: 
  • The two companies are combining their expertise to provide solutions and services to this rapidly evolving industry.
  • The partnership between Bühler and NRGene offers BSF producers a comprehensive solution that incorporates Bühler's high-end equipment and engineering capabilities and NRGene's novel genetics and AI-based genomics tools.
  • We are excited to partner with Bühler as we move towards a cost-efficient industry scaleup," says Dr. Gil Ronen, NRGene's CEO and Founder.
  • Black soldier fly is considered one of the most sustainable meat alternatives for carnivorous pets and farm animals.

USPTO Issues Notice of Allowance to BRAINBox Solutions to Grant Broad U.S. Patent Covering Biomarkers that Correlate to MRI Neuroimaging Findings

Retrieved on: 
Friday, March 17, 2023
DSM-IV codes, National Center for Telehealth & Technology, Patent, Concussion, ALDOC, Nerve injury, SBIR, ATE, Long-term care, Pathology, Brain, TBI, Biomarker, Aldolase C, MRI, Initial, NRGN, Patient, Risk, Algorithm, Diagnosis, Brainbox, Geriatrics, Conditional sentence, Medical imaging, Stroke, Neurogranin

RICHMOND, Va., March 17, 2023 /PRNewswire/ -- BRAINBox Solutions today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to issue to the company a broad patent covering a specific set of biomarkers that correlate to specific neuroimaging findings by standard or advanced MRI methods. The patent is part of the company's extensive and growing intellectual property portfolio covering the use of novel biomarkers in combination with functional tests to diagnose individuals with concussion (mild traumatic brain injury or acute traumatic encephalopathy, ATE) and assess their risk of chronic injury.

Key Points: 
  • RICHMOND, Va., March 17, 2023 /PRNewswire/ -- BRAINBox Solutions today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to issue to the company a broad patent covering a specific set of biomarkers that correlate to specific neuroimaging findings by standard or advanced MRI methods.
  • "This new patent, and our broader portfolio, underlie the BRAINBox TBI family of diagnostic/prognostic point-of-care or main lab delivered tests we are developing for ATE," said Donna Edmonds, CEO of BRAINBox Solutions.
  • The Initial BRAINBox ATE test will include a panel of blood biomarkers and a battery of neurocognitive tests, combined in an easy-to-use application.
  • The new patent will cover the use of eight biomarkers, including Aldolase C (ALDOC) and Neurogranin (NRGN).

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

Retrieved on: 
Tuesday, October 4, 2022
Algorithm, Concussion, Senior advisor, MT3, OPKO Health, Family, Prognosis, Diagnosis, BDNF, Posture, Psychology, Book, Sports medicine, Medtech, Brainbox, NIH, Patent, Athlete, GFAP, MRI, Developing Solutions, Inc, TBI, Neuroimaging, Health, László, J&J, Cuban medical internationalism, PTO, Solution, NFL, University, Unitus Seed Fund, UCLA School of Dentistry, Stryker, Biomarker, LECOM Health Challenge, Forme, Partner, Risk, Intellectual property, Board, Marketing, NSE, NRGN, Medical imaging, Pharmaceutical industry, Medical device, Biology, Medicine

RICHMOND, Va., Oct. 4, 2022 /PRNewswire/ -- BRAINBox Solutions, Inc announced today that the U.S. Patent & Trademark Office (PTO) issued a notice of allowance for a patent covering methods for detection of mild traumatic brain injury (mTBI), also known as concussion, using Brain Derived Neurotrophic Factor (BDNF). BDNF is an important component of the biomarker panel in the multi-modal diagnostic prognostic and prognostic solutions the company is developing for mTBI.

Key Points: 
  • "BRAINBox's test is the first to integrate blood biomarkers with functional testing for both the diagnosis and prognosis of mild TBI," said Donna Edmonds, BRAINBox Solutions' Chief Executive Officer.
  • "The new BDNF patent is an important addition to our broad, worldwide portfolio of patents covering biomarkers related to various aspects of diagnostic use.
  • The newly allowed patent is based on BRAINBox Solutions' discovery that a decrease in blood levels of BDNF alone are sensitive and specific in the detection of mild TBI.
  • BRAINBox Solutions is developing the first AI enabled, multi-modality approach for the diagnosis and prognosis of Mild Traumatic Brain Injury, commonly referred to as a concussion.

Strategic Collaboration to Address the Global Food Crisis: NRGene and Granot Group Develop Elite Varieties for Vertical Farming

Retrieved on: 
Tuesday, August 16, 2022
Food Tech, Technology, Environment, Agriculture, Natural Resources, Artificial Intelligence, Wind, Public relations, Genomics, Kibbutz, Adoption, CEO, Algorithm, Technology, Agriculture, Business, Livestock, Silage, Grain, Research, Environment, Gene editing, Food quality, NRGN, Heritage turkey, Innovation, Partnership, Transport, Water, Seedling, Milk, Ticker, Air pollution, Farm, Goal, Genetics, TASE, Breeding, USD, IPS, Granot

This collaboration will begin with the development of seedlings for use in vertical farming facilities to feed dairy cows.

Key Points: 
  • This collaboration will begin with the development of seedlings for use in vertical farming facilities to feed dairy cows.
  • Furthermore, Granot Group will be entitled to exclusive distribution rights in Israel, and other potential territories worldwide.
  • With the development of specific elite varieties for vertical farming, Granot and NRGene are redefining this paradigm by improving produce, increasing yields, and reducing food prices.
  • NRGene contributes to each step in the agricultural supply chain while enhancing sustainable food production and reducing environmental footprints.

Frost & Sullivan analysts' coverage of NRGene Technologies Ltd.

Retrieved on: 
Tuesday, November 2, 2021
Suntory, TEL, Research, Syngenta, Genomics, TASE, HERE, Agriculture, Frost & Sullivan, NRGN, Rubber industry in Malaysia, Growth, Plant, Solution, Foodservice, Bayer, NIS, Mondelez International, AI, Animal, Fine chemical

TEL AVIV,Israel, Nov. 2, 2021 /PRNewswire/ -- Equity research is published in Frost & Sullivan's Independent Equity Research Program framework.

Key Points: 
  • TEL AVIV,Israel, Nov. 2, 2021 /PRNewswire/ -- Equity research is published in Frost & Sullivan's Independent Equity Research Program framework.
  • NRGene Technologies Ltd (TASE: NRGN) is a global genomics company that provides innovative solutions for many agricultural applications.
  • On January 26, 2021, NRGene closed its TASE listing, raising ~$30M gross according to approx.
  • We deem that NRGene is in strong position for growth due to its initially strong market penetration, scalability potential, know-how, and agile business model.